Wong Wai Keat, Morton Randall P
Department of Otolaryngology, Counties-Manukau District Health Board, P.O. Box 98743, Manukau City, Auckland, New Zealand.
Eur Arch Otorhinolaryngol. 2014 Nov;271(11):3011-9. doi: 10.1007/s00405-013-2857-6. Epub 2013 Dec 14.
There is uncertainty regarding the threshold for recommending elective regional nodal treatment in the management of stage N0 cutaneous squamous cell carcinoma of the head and neck (cSCCHN). Elective treatment in the form of nodal surgery or irradiation is associated with morbidity. However, patients managed with careful observation sometimes present with advanced disease which often require more extensive therapy or may be unsalvageable altogether. We used decision analysis to examine the tradeoffs and benefits of different management approaches in the stage N0 patient. A decision tree comprising the three different treatment strategies was built: surveillance, elective nodal dissection (END) and elective nodal irradiation (ENI). Probabilities of nodal recurrence and likelihood of successful salvage were obtained from the literature. A convenience sample of patients previously treated for metastatic and non-metastatic cSCCHN was interviewed using the standard gamble technique to determine utility for post-treatment health states. Sensitivity analysis was performed and the effect on the expected utility was examined. When the probability of occult metastasis was >19 %, ENI resulted in a higher expected utility than observation. When the probability of occult metastasis exceeds 25 %, END has a higher expected utility compared to observation. Given the current available evidence, a wait-and-see approach is justified in patients with a probability of occult metastases <19 %.
在头颈部皮肤鳞状细胞癌(cSCCHN)N0期的治疗中,关于推荐选择性区域淋巴结治疗的阈值存在不确定性。以淋巴结手术或放疗形式进行的选择性治疗会带来并发症。然而,接受密切观察的患者有时会出现晚期疾病,这通常需要更广泛的治疗,或者可能完全无法挽救。我们使用决策分析来研究N0期患者不同管理方法的权衡和益处。构建了一个包含三种不同治疗策略的决策树:监测、选择性淋巴结清扫术(END)和选择性淋巴结照射(ENI)。淋巴结复发的概率和成功挽救的可能性来自文献。使用标准博弈技术对先前接受转移性和非转移性cSCCHN治疗的患者便利样本进行访谈,以确定治疗后健康状态的效用。进行了敏感性分析,并检查了对预期效用的影响。当隐匿性转移的概率>19%时,ENI的预期效用高于观察。当隐匿性转移的概率超过25%时,与观察相比,END具有更高的预期效用。鉴于目前可用的证据,对于隐匿性转移概率<19%的患者,观望方法是合理的。